Schedule
October, 30th
October, 31th
November, 1st
October, 30th
- 13:40 to 14:00 The theoretical basis of HIPEC- associated Cytoreduction
- 14:00 to 14:20 Theoretical bases and possible technologies for PIPAC
- 14:20 to 14:40 Is free opioid technique in cytoreduction associated with HIPEC a reality?
- 14:40 to 15:00 And selection of patients for extensive cytoreduction in peritoneal pseudomyxoma
- 15:00 to 15:20 Cytoreduction associated with HIPEC in peritoneal pseudomyxoma: peritonei today
- 15:20 to 15:40 Possible HIPEC regimens in the initial approach and in the recurrence of peritoneal pseudomyxomas
- 15:40 to 16:00 Discussion
- 12:00 to 13:30 Lunch
- 14:20 to 14:40 Técnica opioide free em citorredução associada à HIPEC é uma realidade?
- 14:40 to 15:00 Preparo e seleção de pacientes para citorredução extensa no pseudomixoma
- 15:00 to 15:20 Cytoreduction associated with HIPEC in peritoneal pseudomyxoma: peritonei today
- 15:20 to 15:40 Regimes de HIPEC possíveis na abordagem inicial e na recidiva dos pseudomixomas
- 15:40 to 16:00 Discussion
- 16:00 às 16:20 Break
- 16:20 to 16:40 Technical strategies for cytoreduction in challenging scenarios( high PCI)
- 16:40 to 17:00 Maximal tumor debulking and HIPEC in two strokes – a possible reality?
- 17:00 to 17:20 Is cytoreduction associated with HIPEC in non-OCC scenarios possible?
- 17:20 to 17:40 A peritoneal pseudmyxoma not of appendix origin: what is the role of HIPEC?
- 17:40 to 18:00 In which scenarios does ReHIPEC have space?
- 18:00 to 18:20 Discussion
- 18:30 to 19:00 Cocktail
- 19:00 to 19:20 Official Opening of the Congress
- 19:20 to 19:40 Present, past and future in the treatment of peritoneal carcinomatosis
- 19:40 to 20:20 Presentation of the male choir of Bom Principio
October, 31th
- 08:00 to 08:20 Clinical and histological selection of mesothelioma for cytoreduction associated with HIPEC
- 08:20 to 08:40 An evaluation of the Types of peritoneal perfusion regimens in mesothelioma
- 08:40 to 09:00 Total vs selective peritonectomy: What to do when dealing with benign multicystic mesothelioma?
- 09:00 to 09:20 The possibility of large wall resections in HIPEC-associated cytoreduction
- 09:20 to 09:40 Alternatives to the non- candidate patient in curative surgical treatment
- 09:40 to 10:00 Discussion
- 10:00 to 10:20 Break
- 08:00 às 10:00 Liga Feminina
- 10:00 to 10:20 Break
- 10:20 às 12:00 SOCIEDADE BRASILEIRA DE PATOLOGIA – SBP
- 12:00 to 13:30 Lunch break
- 13:40 às 16:00 COLÉGIO BRASILEIRO DE RADIOLOGIA E DIAGNÓSTICO POR IMAGEM – CBR
- 16:00 às 16:20 Break
- 16:20 às 18:00 ASSOCIAÇÃO DE MEDICINA INTENSIVA BRASILEIRA – AMIB
- 10:20 to 10:40 Incorporation of HIPEC into SUS(NHS), a victory for the patient?
- 10:40 to 11:00 Protocol construction for conitec: my experience
- 11:20 to 12:00 Discussion
- 12:00 to 13:30 Lunch break
- 13:40 to 14:00 Selecting the best patient for HIPEC-associated cytoreduction in colonrectal carcinomatosis
- 14:00 to 14:20 Cytoreduction associated with HIPEC still has room after Prodige 7
- 14:20 to 14:40 Is colon cytoreduction associated with HIPEC for a high-risk patient still a possibility?
- 14:40 to 15:00 Cólon
- 15:00 to 15:20 Discussion
- 15:20 to 15:40 What to expect when using PIPAC as an alternative in the treatment of colon carcinomatosis?
- 15:40 to 16:00 What to expect when using systemic chemotherapy in the treatment of colon carcinomatosis?
- 16:00 às 16:20 Break
- 16:20 to 16:40 Cólon
- 16:40 to 17:00 Cólon
- 17:00 to 17:20 Discussion
- 17:20 to 17:30 A Study analysing tumour sensitivity to systemic chemotherapy
- 17:30 to 18:00 I remember this complication
November, 1st
- 08:00 to 08:20 What is the ideal patient for HIPEC ovarian cancer? Is there space for molecular selection?
- 08:20 to 08:40 Role of cytoreductive surgery for rec. ovarian cancer
- 08:40 to 09:00 Role of cytoreductive surgery for rec. ovarian cancer
- 09:00 to 09:20 Discussion
- 09:20 to 09:40 The potential role of HIPEC in association with modern systemic therapies
- 09:40 to 10:00 Is OVHIPEC the best regimen in HIPEC-associated cytoreduction?
- 10:00 to 10:20 Break
- 10:20 to 10:40 Does PIPAC have a role in ovarian cancer?
- 10:40 to 11:00 Discussion
- 08:00 to 08:20 Argentina
- 08:20 to 08:40 Chile HIPEC
- 08:40 to 09:00 Brasil
- 09:00 to 09:20 Paraguai: Hipec in Paraguai what is our reality?
- 09:20 to 09:40 Uruguai
- 09:40 to 10:00
- 10:00 to 10:20 Break
- 10:20 to 10:40 Bolivia
- 10:40 to 11:00 Peru
- 11:00 às 11:20 Colombia
- 11:20 to 11:40 Equador
- 11:40 to 12:00 México- Hipec in the Mexico let`s talk about
- 12:00 às 14:00 Lunch break
- 14:00 às 18:00 APRESENTAÇÕES LIVRES
- 18:00 Closing
- 11:00 to 11:20 Immunonutrition in HIPEC
- 11:20 to 11:40 Who is the ideal patient for HIPEC in stomach cancer?
- 11:40 to 12:00 Is prophylactic HIPEC for stomach cancer a possible strategy?
- 12:00 to 12:15 Discussion
- 12:15 to 14:00 Lunch break
- 14:00 to 14:20 Systemic chemo with intraperitoneal chemo talk of the treatment of stomach neoplasms?
- 14:20 to 14:40 Discussion
- 14:40 to 15:00 How PIPAC can change the approach to carcinomatosis in stomach cancer
- 15:00 to 15:20 What is the best intraperitoneal chemotherapy regimen in HIPEC?
- 15:20 to 15:40 Systemic chemotherapy in gastric carcinomatosis: what can we expect?
- 15:40 to 16:00 Discussion
- 16:00 às 16:20 Break
- 16:20 to 16:40 Latin registration
- 16:40 to 17:00 How large database can a in registration influence our clinical practice?
- 17:00 to 17:20 HIPEC in other pathologies: bigrenap data
- 17:20 to 17:40 Video on carcinomatosis: cytoreduction and HIPEC
- 17:40 to 18:00 Intraperitoneal chemotherapy regimens: future perspectives!
- 18:00 Closing